Navigating the new European HTA Landscape.

 

Capture d’écran 2026-07-09 à 12.08.52
The European HTA Regulation is transforming market access.
Our position paper explains how pharmaceutical and MedTech companies can adapt their evidence-generation strategy to succeed under the new Joint Clinical Assessment (JCA) framework across Europe and the evolving UK pathway.

 

Discover key insights on:

  • Understanding the new EU HTA Regulation and Joint Clinical Assessments (JCA)

  • Comparing the European and UK approaches to HTA and reimbursement

  • Designing integrated evidence-generation strategies from early development

  • Building clinical and economic evidence that meets multiple stakeholder expectations ​

  • Preparing your organization for successful market access in the new HTA landscape​

Register to download
the White Paper

Discover our latest news

Expert Q&As

Launching in EU - Q&A 8

What risk areas should we pay special attention to (pharmacovigilance, legal, compliance, etc.) when launching in Europe?

Read more

Articles

Make France your Next Success Story

Why Setting Up in France Feels Like Climbing a Mountain—and How AzurBio Can Help!

Read more

Expert Q&As

First interactions with EMA - Q&A 1

What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?

Read more

Looking to enter the EU market?
Contact us today.

Contact us